Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun:42:3-8.
doi: 10.1016/j.prrv.2020.05.002. Epub 2020 May 26.

CFTR modulator therapies - Effect on life expectancy in people with cystic fibrosis

I M Balfour-Lynn  1 , J A King  2
Affiliations
Review

CFTR modulator therapies - Effect on life expectancy in people with cystic fibrosis

I M Balfour-Lynn et al. Paediatr Respir Rev. 2022 Jun.

Abstract

CFTR modulators have dramatically changed the clinical course of CF in those fortunate enough to receive them. Inevitably, randomised controlled trials during the development of these drugs are too short to use mortality as an outcome. Evidence for their effect on life expectancy are best gained from real world registry studies specifically looking at mortality, but these are only available for ivacaftor to date. Therefore, indirect evidence must be obtained by looking at outcomes known to affect mortality and seeing the effect of these drugs on those outcomes.

Keywords: CFTR modulators; Cystic fibrosis; Mortality; Prognosis.

PubMed Disclaimer

References

    1. Harman K., Dobra R., Davies J.C. Disease-modifying drug therapy in cystic fibrosis. Paediatr Respir Rev. 2018;26:7–9. doi: 10.1016/j.prrv.2017.03.008. - DOI - PubMed
    1. Keogh R.H., Szczesniak R., Taylor-Robinson D., Bilton D. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. J Cyst Fibros. 2018;17:218–227. doi: 10.1016/j.jcf.2017.11.019. - DOI - PMC - PubMed
    1. MacKenzie T., Gifford A.H., Sabadosa K.A., Quinton H.B., Knapp E.A., Goss C.H., et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med. 2014;19(161):233–241. doi: 10.7326/M13-0636. - DOI - PMC - PubMed
    1. Stephenson A.L., Stanojevic S., Sykes J., Burgel P.R. The changing epidemiology and demography of cystic fibrosis. Presse Med. 2017;46(6 Pt 2):e87–e95. doi: 10.1016/j.lpm.2017.04.012. - DOI - PubMed
    1. Bell S.C., Mall M.A., Gutierrez H., Macek M., Madge S., Davies J.C., et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8:65–124. doi: 10.1016/S2213-2600(19)30337-6. - DOI - PMC - PubMed

MeSH terms

Substances